Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 411

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 411
---
,200,000 shares of common stock and a non-cash contribution by the other
founder for 2,000,000 shares of common stock. The non-cash contribution consisted of all of the founders’ rights, title, and interest
in any intellectual property, proprietary property or other property of a similar nature related to the business to be conducted by the
Company involving methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases.

In the year ended May 31, 2023, the Company issued
101,806 shares of common stock upon conversion of an outstanding convertible note amounting to $606,662. See Note 7.

Founder Contributions

In the year ended May 31, 2023, the Company sold 14,265 shares of common
stock to one of its founders for $100,000.

In the years ended May 31, 2024 and 2023, its
founders also made contributions to the Company in the form of below market interest rates on loans and in the form of uncompensated services.
the Company recorded discounts on founder notes payable of $35,063 and $101,221 in the years ended May 31, 2024 and 2023, respectively,
as additional paid-in capital. The Company expensed $0 and $18,348 in the years ended May 31, 2024 and 2023, respectively, for the estimated
value of uncompensated services, and recorded the amounts as additional paid-in capital.

<div align='center'>F-15</div>

Stock Option Plans

The Company maintains stock option plans, under
which shares are available for issuance of stock-based awards under terms established by the board of directors. Through May 31, 2024,
awards under the plans generally consisted of options with exercise prices equal to fair market value, vesting and service conditions
of 18 months to three years without market or performance conditions and ten-year lives. Options granted in the year ended May 31, 2023
for an aggregate of 246,000 shares are subject to vesting conditions related to research and financing milestones. As of May 31, 2024,
219,447 shares remain available for future grants under the 2014 Stock Option Plan, which expires in September 2024, and 600,000 shares
remain available for future grant under the 2024 Stock Option Plan. The number of shares available under the 2024 Stock